Passage Bio, Inc. (NASDAQ:PASG – Get Rating) – Stock analysts at Wedbush decreased their Q1 2023 earnings estimates for shares of Passage Bio in a research report issued to clients and investors on Monday, March 6th. Wedbush analyst L. Chico now forecasts that the company will earn ($0.50) per share for the quarter, down from their previous estimate of ($0.44). Wedbush has a “Outperform” rating on the stock. The consensus estimate for Passage Bio’s current full-year earnings is ($1.92) per share. Wedbush also issued estimates for Passage Bio’s Q2 2023 earnings at ($0.51) EPS, Q3 2023 earnings at ($0.52) EPS, Q4 2023 earnings at ($0.42) EPS, FY2023 earnings at ($1.92) EPS, FY2024 earnings at ($1.57) EPS, FY2025 earnings at ($1.47) EPS, FY2026 earnings at ($1.37) EPS and FY2027 earnings at ($0.97) EPS.
Passage Bio (NASDAQ:PASG – Get Rating) last announced its quarterly earnings data on Monday, March 6th. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.02). During the same period in the previous year, the firm posted ($0.93) earnings per share.
Passage Bio Stock Down 4.6 %
NASDAQ PASG opened at $1.25 on Thursday. The business’s fifty day simple moving average is $1.45 and its 200-day simple moving average is $1.43. The firm has a market cap of $68.28 million, a PE ratio of -0.50 and a beta of 1.03. Passage Bio has a 52 week low of $1.04 and a 52 week high of $3.56.
Institutional Trading of Passage Bio
Several institutional investors have recently added to or reduced their stakes in PASG. Annandale Capital LLC lifted its stake in Passage Bio by 35.8% during the fourth quarter. Annandale Capital LLC now owns 54,338 shares of the company’s stock worth $75,000 after purchasing an additional 14,338 shares in the last quarter. BML Capital Management LLC acquired a new position in Passage Bio during the 4th quarter worth about $466,000. GSA Capital Partners LLP lifted its stake in Passage Bio by 25.4% during the 4th quarter. GSA Capital Partners LLP now owns 106,836 shares of the company’s stock worth $147,000 after acquiring an additional 21,640 shares in the last quarter. New York Life Investment Management LLC boosted its holdings in Passage Bio by 12.7% during the 4th quarter. New York Life Investment Management LLC now owns 182,978 shares of the company’s stock valued at $253,000 after acquiring an additional 20,617 shares during the period. Finally, Bailard Inc. acquired a new position in Passage Bio in the 4th quarter valued at about $217,000. Institutional investors and hedge funds own 76.99% of the company’s stock.
About Passage Bio
Passage Bio, Inc, a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease.
- Get a free copy of the StockNews.com research report on Passage Bio (PASG)
- Fossil Group: Should You Bet On Consumer Discretionary In 2023?
- BJ’s Wholesale Club Stock Moves Higher After Strong Results
- Monthly Realty Income is About to Get Bigger
- 3 Large Cap Dividend Challengers for Millennial Investors
- Sea Ltd Is On The Verge Of A 100% Rally, Should You Buy?
Receive News & Ratings for Passage Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Passage Bio and related companies with MarketBeat.com's FREE daily email newsletter.